Submissions from 2024
Estimation of the optimal radiotherapy utilization rate for childhood neuroblastoma, Azumi Fukushima, Varsha Hande, Katherine Wakeham, Michael Barton, Mohamed Zaghloul, Daniel Moreira, Nickhill Bhakta, Kathy Pritchard-Jones, Bilal Mazhar Qureshi, and Michael Sullivan
Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies, Mansoor Saleh; Minal Barve; Vivek Subbiah; Kyriakos Papadopoulos; Daniel Morgensztern; Niharika Mettu; Sameek Roychowdhury,; Iben Spanggaard; Incyte International Biosciences Sàrl, Switzerland; and Chenwei Tian
Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies, Mansoor Saleh, Minal Barve, Vivek Subbiah, Kyriakos Papadopoulos, Daniel Morgensztern, Niharika Mettu, Sameek Roychowdhury, Iben Spanggaard, Maria Luisa Veronese, and Chenwei Tian
Regulatory approval of clinical trials: is it time to reinvent the wheel?, Mansoor Saleh, Karishma Sharma, Aisleen Shamshudin, Innocent Abayo, Stacey Gondi, and Noureen Karimi
Nutrient intake and nutritional status of blood cancer patients at a tertiary hospital in India: A cross-sectional descriptive analysis of leukemia, lymphoma and multiple myeloma, Enock Topisia and Loise Wamahiga Wang’ondu
Prediction of cardiovascular risk factors from retinal fundus photographs: Validation of a deep learning algorithm in a prospective non-interventional study in Kenya, Tom White, Viknesh Selvarajah, Fredrik Wolfhagen, Nils Svangård, Gayathri Mohankumar, Peter Fenici, Kathryn Rough, Nelson Onyango, Mansoor Saleh, and Innocent Abayo
Submissions from 2023
A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer, Ernest Nadal, Mansoor Saleh, Santiago Aix, Maria Ochoa-de-Olza, Sandip Patel, Scott Antonia, Yumin Zhao, Ivelina Gueorguieva, Michael Man, and Shawn Estrem
Breast cancer clinical trials in East Africa, Karishma Sharma, Joseph Abuodha, Manel Haj Mansour, Noureen Karimi, Diana Omare, Yuashita Hussein, and Mansoor Saleh
Submissions from 2022
Promoting Best Practice in Cancer Care in Sub Saharan Africa, Karishma Sharma, Shahin Sayed, and Mansoor Saleh
Submissions from 2020
Clinical Investigator Training Program (CITP) – A practical and pragmatic approach to conveying clinical investigator competencies and training to busy clinicians., Mansoor Saleh, Gurudatta Naik, Penelope Jester, Cynthia Joiner, Elizabeth Westfall, David W. Kimberlin, James Willig, David Redden, Juliette Southworth, and Mark T. Dransfield
Submissions from 2017
Abstract A12: Ethnic differences in the clinical and pathological characteristics of breast cancer among Kenyan women, Shahin Sayed, Zahir Moloo, Ronald Wasike, Asim Jamal, Peter Bird, Maya Palakal, Gretchen Gierach, and Mansoor Saleh
Submissions from 2016
Breast camps for awareness and early diagnosis of breast cancer in countries with limited resources: A multidisciplinary model from Kenya, Shahin Sayed, Zahir Moloo, Anthony Ngugi, Rose Ndumia, Ronald Wasike, Mansoor Saleh, Anderson Mutuiri, Abdul Aziz, Kibet Kibor, and Jonathan Wawire
Submissions from 2012
A randomized, phase II, multicenter, double-blind, placebo-controlled study evaluating onartuzumab (MetMAb) in combination with mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer., Johanna Bendell, Thomas Ervin, David Gallinson, Jaswinder Singh, James Alfred Wallace, Mansoor Saleh, Marcy Vallone, and Stephen Paul Hack
O-0022 X-Pect study results: A phase III randomized study of perifosine plus capecitabine vs. placebo plus capecitabine in refractory mCRC patients, Johanna Bendell, Thomas Ervin, Neil Senzer, Donald Richards, Irfan Firdaus, Craig Lockhart, Allen Cohn, Mansoor Saleh, Peter Sportelli, and Lesa Gardner
Phase I study of bosutinib, a src/Abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors, Adil Daud, Smitha Krishnamurthi, Mansoor Saleh, Barbara Gitlitz, Mitesh Borad, Philip Gold, Elena Chiorean, Gregory Springett, Richat Abbas, and Shefali Agarwal
A phase II study of the androgen signaling inhibitor ARN-509 in patients with castration-resistant prostate cancer (CRPC)., Dana Rathkopf, Neal Shore, Emmanuel Antonarakis, William Berry, Joshi Alumkal, Ronald Tutrone, Mansoor Saleh, Charles Redfern, Ralph Hauke, and Glenn Liu
964TiP - ARN-509 in Men with metastatic castration-resistant prostate cancer (CRPC), D. Rathkopf, E.S. Antonarakis, N.D. Shore, R. Tutrone, J. Alumkal, C.J. Ryan, Mansoor Saleh, R. Hauke, E. Chow-Maneval, and H.I. Scher
Submissions from 2011
Phase Ib results of c-MET inhibitor ARQ 197 in combination with gemcitabine in a cohort of patients (pts) with advanced breast, ovarian, and uterine tumors., L. H. Camacho, S. Pant, Mansoor Saleh, G. Abbadessa, J. Kazakin, B. E. Schwartz, and J. C. Bendell
Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study, Gregory Cheng, Mansoor Saleh, Claus Marcher, Sandra Vasey, Bhabita Mayer, Manuel Aivado, Michael Arning, Nicole Stone, and James Bussel
Phase III Study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2–normal, node-positive breast cancer: BCIRG-005 trial, Wolfgang Eiermann, Tadeusz Pienkowski, John Crown, Saeed Sadeghi, Miguel Martin, Arlene Chan, Mansoor Saleh, Sandeep Sehdev, Louise Provencher, and Vladimir Semiglazov
Pooled safety results from SPIRITT: A multicenter, open-label, randomized, phase II study of FOLFIRI with panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC)., J. R. Hecht, S. R. Dakhil, Mansoor Saleh, B. Piperdi, M. Cline-Burkhardt, D. M. Kocs, L. C. DeMarco, L. Chen, K. Krishnan, and A. L. Cohn
Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-Like receptor 9 Agonist) as first-line treatment for advanced non–small-cell lung cancer, Vera Hirsh, Luis Paz-Ares, Michael Boyer, Rafael Rosell, Gary Middleton, Wilfried Eberhardt, Aleksandra Szczesna, Pavel Reiterer, Mansoor Saleh, and Oscar Arrieta
Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: A phase III, randomized, open-label trial, Nicholas Robert, Mansoor Saleh, Devchand Paul, Daniele Generali, Laurent Gressot, Mehmet Copur, Adam Brufsky, Susan Minton, Jeffrey Giguere, and John W. Smith II
Safety and efficacy of extended treatment with eltrombopag in adults with chronic immune thrombocytopenia (ITP) from June 2006 to February 2011,, Mansoor Saleh, Gregory Cheng, James Bussel, Paul Burgess, Lisa Marcello, Christine Bailey, and Andres Brainsky
Pathologic characteristics of breast cancer with special emphasis on prevalence of triple-negative breast cancer from Kenya: A 4-year experience., Shahin Sayed, Zahir Moloo, Ronald Wasike, RR Chauhan, A Ndonga, ME Trinkaus, Y Rahim, H Wedad, and Mansoor Saleh
P1-12-10: Phase II Study Evaluating Lapatinib (L) in Combination with Albumin Bound Paclitaxel (ab-Pac) in Women Who Have Received 0–1 Chemotherapy Regimen for HER2 Overexpressing (HER2+) Metastatic Breast Cancer (MBC)., DA Yardley, L Hart, L Bosserman, Mansoor Saleh, DM Waterhouse, P Richards, MK Hagan, ML DeSilvio, JM Mahoney, and Y Nagarwala
Submissions from 2010
Incidence of thromboembolic events across eltrombopag clinical trials In chronic immune thrombocytopenia (ITP), James Bussel, Gregory Cheng, Mansoor Saleh, Bhabita Mayer, Sandra Y. Vasey, and Andres Brainsky
Phase II Trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer, Alison Conlin, Andrew Seidman, Ariadne Bach, Diana Lake, Maura Dickler, Gabriella D'Andrea, Tiffany Traina, Michael Danso, Adam Brufsky, and Mansoor Saleh
Association of black race and outcomes in patients with nonmetastatic triple-negative breast cancer (TNBC): Results from a U.S. local oncology practice., B. A. Feinberg, L. Chen, L. Zhao, J. W. Gilmore, S. Haislip, Mansoor Saleh, S. D. Sullivan, and N. P. Christiansen
Pilot trial of preoperative (Neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor— or progesterone receptor—positive breast cancer, Andres Forero-Torres, Mansoor Saleh, Janice A. Galleshaw, Cheryl F. Jones, Jatin Shah, Ivor Percent, Lisle Nabell, John Carpenter, Carla Falkson, and Helen Krontiras
Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5), Andres Forero-Torres, Jatin Shah, Tina Wood, James Posey, Ronda Carlisle, Catherine Copigneaux, Feng (Roger) Luo, Slawomir Wojtowicz-Praga, Ivor Percent, and Mansoor Saleh
Tositumomab and I 131 tositumomab achieves complete remissions lasting > 10 years in patients with chemotherapy-refractory low-grade and transformed B-cell lymphomas, Mark Kaminski, Andrew Zelenetz, Oliver Press, Mansoor Saleh, John Leonard, Louis Fehrenbacher, Andrew Lister, Thierry Horner, Vanessa Williams, and Thomas Lin
Correlation of GPNMB expression with outcome in breast cancer (BC) patients treated with the antibody–drug conjugate (ADC), CDX-011 (CR011-vcMMAE)., Mansoor Saleh, J. C. Bendell, A. Rose, P. Siegel, L. L. Hart, S. Sirpal, S. F. Jones, E. Crowley, R. Simantov, and L. T. Vahdat
EXTEND study update: Safety and efficacy of eltrombopag In adults with chronic immune thrombocytopenia (ITP) From June 2006 to February 2010, Mansoor Saleh, Gregory Cheng, James Bussel, Huiping Sun, Bhabita Mayer, Christine Bailey, and Andres Brainsky
Pemetrexed with or without Matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer, Joan Schiller, Joachim von Pawel, Philipp Schütt, Rafat Ansari, Michael Bijoy Thomas, Mansoor Saleh, Robert D. McCroskey, Wolfgang Pfeife, Thomas Marsland, and Goetz Kloecker
Submissions from 2009
A phase (Ph) I/II study of CR011-VcMMAE, an antibody-drug conjugate, in patients (Pts) with locally advanced or metastatic breast cancer (MBC)., H. Burris, Mansoor Saleh, J. Bendell, L. Hart, A. Rose, Z. Dong, P. Siegel, M. Crane, D. Donovan, and E. Crowley
Thromboembolic events observed in eltrombopag clinical trials in chronic immune thrombocytopenic purpura., James Bussel, Gregory Cheng, Mansoor Saleh, Sandra Vasey, Manuel Aivado, and Andres Brainsky
High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: High rates of rapid cytogenetic and molecular responses, Jorge E. Cortes, Hagop M. Kantarjian, Hagop M. Kantarjian, Stuart L. Goldberg, Bayard L. Powell, Francis J. Giles, Meir Wetzler, Luke Akard, John M. Burke, and Mansoor Saleh
Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma, Sven de Vos, André Goy, Shaker R. Dakhil, Mansoor Saleh, Peter McLaughlin, Robert Belt, Christopher R. Flowers, Mark Knapp, Lowell Hart, and Dipti Patel-Donnelly
BCIRG 005 main efficacy analysis: a phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC→T) in women with Her-2/neu negative axillary lymph node positive early breast cancer., W Eiermann, T Pienkowski, J Crown, L Chap, M Pawlicki, M Martin, Mansoor Saleh, S Sehdev, L Provencher, and G Von Minckwitz
Update of a phase II trial of bevacizumab in combination with hormonal therapy to reverse acquired estrogen independence in metastatic breast cancer patients, C. Falkson, J. Rossman, L. Nabell, J. Carpenter, A. Forero, Y. Kim, and Mansoor Saleh
A pilot trial of pre-operative (Neoadjuvant) letrozole in combination with bevacizumab in post-menopausal women with newly diagnosed estrogen and/or progesterone receptor positive breast cancer., A. Forero, Mansoor Saleh, J. Galleshaw, C. Jones, J. Shah, I. Percent, L. Nabell, J. Carpenter, C. Falkson, and H. Krontiras
A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate, in patients (pts) with locally advanced or metastatic breast cancer (MBC), N. Peacock, Mansoor Saleh, J. Bendell, A. A. Rose, Z. Dong, P. M. Siegel, E. Crowley, R. Simantov, and L. Vahdat
Abstract #3594: A Phase 1 randomized crossover oral picoplatin bioavailability pharmacokinetics and pharmacodynamics study, Angelica Phillips, Mansoor Saleh, Lorrin Yee, Sunil Sharma, Scott Houston, David Karlin, Hazel Breitz, Robert De Jager, and Robert Earhart
Long-term treatment of chronic immune thrombocytopenic purpura with oral eltrombopag: results from the EXTEND Study., Mansoor Saleh, James Bussel, Gregory Cheng, Balkis Meddeb, Bhabita Mayer Mayer, Christine Bailey, and Manuel Aivado
Results of bone marrow examinations in patients with chronic immune thrombocytopenic purpura treated with eltrombopag, Mansoor Saleh, James Bussel, Oliver Meyer, Henrik Frederiksen, Diane Johnni, Manuel Aivado, and Andres Brainsky
Analysis of the impact and burden of illness of adult chronic ITP in the US, Mansoor Saleh, Maxine Fisher, and Kelly M. Grotzinger
Subcutaneous Injections of low-dose anti-CD20 veltuzumab for treatment of relapsed immune thrombocytopenia (ITP)., Mansoor Saleh, Howard Liebman, Zale Bernstein, George Negrea, James B. Bussel, Anthony C. Onyegbula, Charles Farber, Rashid Abassi, Thomas M. Cosgriff, and Kenneth Pennington
A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC), M.A. Socinski, Mansoor Saleh, D.F. Trent, T.W. Dobbs, L.M. Zehngebot, M.A. Levine, R. Bordoni, and P.J. Stella
A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer, Thomas E. Stinchcombe, Daniel S. Bradford, Thomas A. Hensing, Renato V. LaRocca, Mansoor Saleh, Tracey Evans, Kamal Bakri, and Mark A. Socinski
Submissions from 2008
Safety and efficacy of long-term treatment with oral eltrombopag for chronic idiopathic thrombocytopenic purpura., James Bussel, Gregory Cheng, Mansoor Saleh, Balkis Meddeb, Christine Bailey, Nicole Stone, and Manuel Aivado
Efficacy and safety of repeated intermittent treatment with eltrombopag in patients with chronic idiopathic thrombocytopenic purpura., James Bussel, Bethan Psaila Psaila, Mansoor Saleh, Sandra Vasey, Bhabita Mayer, Nicole Stone, and Michael Arning
Eltrombopag Delivers Clinical Benefit in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients Not Achieving Platelet Counts ≥50,000/μL - Data from the EXTEND Study., Gregory Cheng, James Bussel, Mansoor Saleh, Balkis Meddeb, Maria E De Obaldia, Manuel Aivado, and Nicole Stone
Oral Eltrombopag for the long-term treatment of patients with chronic idiopathic thrombocytopenic purpura: results of a phase III, double- blind, placebo-controlled Study (RAISE), Gregory Cheng, Mansoor Saleh, James Bussel, Claus Marcher, Sandra Vasey, Bhabita Mayer, Manuel Aivado, Michael Arning, and Nicole Stone
A phase II trial investigating if bevacizumab in combination with hormone therapy will reverse acquired estrogen independence in metastatic breast cancer patients, C. Falkson, J. F. Rossman, L. Nabell, J. Carpenter, Mansoor Saleh, J. O'Malley, and A. Forero
Pharmacoeconomic evaluation of hypomethylating agents used for the treatment of MDS, Bruce Feinberg, James Gilmore, Sally Haislip, Carlos Franco, Tom Gondesen, and Mansoor Saleh
Oral eltrombopag treatment reduces the need for concomitant medications in patients with chronic idiopathic thrombocytopenic purpura., Patrick Fogarty, James Bussel, Gregory Cheng, Mansoor Saleh, Balkis Meddeb, Christine Bailey, and Andres Brainsky
A pilot open-label trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed operable breast cancer, A. Forero-Torres, J. Galleshaw, C. Jones, I. Percent, L. Nabell, J. Carpenter, C. Falkson, H. Krontiras, K. Bland, and Mansoor Saleh
Low-dose humanized Anti-CD20 monoclonal antibody (MAb), veltuzumab, in adult immune thrombocytopenic purpura (ITP): Initial results of a phase I/II study., Howard Liebman, Mansoor Saleh, Rashid Abassi, Thomas Cosgriff, Nick Teoh, Matthew Leoni, William Wegener, and David Goldenberg
Eltrombopag Is efficacious in patients with refractory chronic idiopathic thrombocytopenic purpura (ITP) - Data from the EXTEND study, Mansoor Saleh, James Bussel, Gregory Cheng, Balkis Meddeb, Paul Burgess, Maria E De Obaldia E De Obaldia, Nicole Stone, and Manuel Aivado
A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas, Mansoor Saleh, I. Percent, T. E. Wood, J. Posey III, J. Shah, R. Carlisle, S. Wojtowicz-Praga, and A. Forero-Torres
Phase II study of weekly nanoparticle albumin bound (nab)paclitaxel with carboplatin and trastuzumab as 1st-line therapy for HER2-positive metastatic breast cancer (MBC), A. D. Seidman, A. K. Conlin, A. Bach, A. M. Brufsky, Mansoor Saleh, D. Lake, M. N. Dickler, G. D'Andrea, T. A. Traina, and C. A. Hudis
Submissions from 2007
Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel, Tomasz Beer, Celestia Higano, Mansoor Saleh, Robert Dreicer, Gary Hudes, Joel Picus, Mark Rarick, Louis Fehrenbacher, and Alison Hannah
Long-term safety and efficacy of oral eltrombopag for the treatment of subjects with Idiopathic Thrombocytopenic purpura (ITP): Preliminary data from the EXTEND study., James Bussel, Gregory Cheng, Lidia Kovaleva, Mansoor Saleh, Balkis Meddeb, Bhabita Mayer, J. Lee Fraser, and Manuel Aivado
Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura, James Bussel, Bhabita Mayer, Nicole Stone, Michael Arning, Drew Provan, and Mansoor Saleh
Changing treatment paradigms for myelodysplastic syndromes in a community oncology practice: Georgia cancer specialists' experience, Bruce Feinberg, James Gilmore, Wendy Hawke Lenz, Carlos Franco, Tom Gondesen, and Mansoor Saleh
Bendamustine in non-hodgkin lymphoma: The double-agent that came from the cold war, Andres Forero-Torres and Mansoor Saleh
A study of pre-operative (neoadjuvant) letrozole in combination with bevacizumab in post-menopausal women with newly diagnosed operable breast cancer: A preliminary safety report, A. Forero-Torres, I. Percent, J. Galleshaw, L. Nabell, J. Carpenter, C. Falkson, C. Jones, H. Krontriras, J. De Los Santos, and Mansoor Saleh
A study of pre-operative (neoadjuvant) letrozole in combination with bevacizumab in post-menopausal women with newly diagnosed operable breast cancer: A preliminary safety report, A. Forero-Torres, I. Percent Percent, J. Galleshaw, L. Nabell, C. Falkson, C. Jones, H. Krontriras, J. De Los Santos, and Mansoor Saleh
Cost comparison of XELOX compared to FOLFOX4 with or without bevacizumab (bev) in metastatic colorectal cancer, L. Garrison, J. Cassidy, Mansoor Saleh, F. Lee, R. Mena, J. Fuloria, V. Chang, T. Ervin, P. Stella, and L. Saltz
B1-06: Multicenter, randomized study of docetaxel versus docetaxel plus oblimersen in patients previously treated for non-small cell lung cancer (NSCLC), Roy S. Herbst, Rafat Ansari, V Gorbunova, G Manikhas, Mansoor Saleh, Thomas Boyd, Christopher Azzoli, Francisco Robert, Loretta Itri, and Robert Chapman
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT Investigators, Tomasz M. Beer, Christopher W. Ryan, Peter M. Venner, Daniel P. Petrylak, Gurkamal S. Chatta, J. Dean Ruether, Charles H. Redfern, Louis Fehrenbacher, Mansoor Saleh, and David Waterhouse
Extended phase I trial of the oral pan-Bcl-2 inhibitor AT-101 by multiple dosing schedules in patients with advanced cancers, H. C. Pitot, Mansoor Saleh, J. Holmlund, J. Maleski, and A. Forero
Randomized phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small cell lung cancer (NSCLC), Mansoor Saleh, M. A. Socinski, D. Trent, T. Dobbs, L. M. Zehngebot, M. A. Levine, and P. J. Stella
3003 ORAL cetuximab plus irinotecan in patients (pts) with metastatic colorectal cancer (mCRC) failing prior oxaliplatin-based therapy: the EPIC trial, Werner Scheithauer, A. Sobrero, H.J. Lenz, J. Maurel, M. Lutz, G. Middleton, Mansoor Saleh, A. Zubel, K. Williams, and H.A. Burris III
Phase 2 study of MKC-1 in patients (pts) with metastatic breast cancer (MBC) who have failed prior therapy with an anthracycline (A) and taxane (T), L. Sylvester, L. Laufman, K. Jabboury, Mansoor Saleh, K. Tkaczuk, F. Volterra, J. Arnott, A. Hannah, C. Sidor, and A. Hannah
Submissions from 2006
Bexarotene improves median survival (MS) in untreated, advanced NSCLC, when given in combination with carboplatin/paclitaxel, R. Bordoni, Mansoor Saleh, S. Khanwani, T. Page, M. Auerbach, F. Steinbaum, and R. Ghalie
Analysis of bleeding in patients with immune thrombocytopenic purpura (ITP): A randomized, double-blind, placebo-controlled trial of eltrombopag, an oral platelet growth factor., James B. Bussel, Gregory Cheng, Mansoor Saleh, Lidia Kovaleva, Nicole Stone, Bhabita Mayer, Julian Jenkins, and Andrew Provan
Eltrombopag, a novel, oral platelet growth factor, increases platelet counts in thrombocytopenic patients and healthy subjects, J. Bussel, Mansoor Saleh, D. Provan, N. Stone, J. M. Hamilton, H. Hassani, B. Mayer, J. Uhl, J. Jenkins, and J. Glaspy
Phase 2 study of bortezomib weekly or twice weekly plus rituximab in patients with follicular (FL) or marginal zone (MZL) lymphoma: final results., Sven De Vos, Shaker R. Dakhil, Peter McLaughlin McLaughlin, Mansoor Saleh, Robert Belt, Christopher Flowers, Charles Holladay, Mark Knapp, Anthony Boral, and Tracy Zhang
The safety profile of eltrombopag, a novel oral platelet growth factor, in thrombocytopenic patients and healthy subjects, D. Provan, Mansoor Saleh, S. Goodison, R. Rafi, N. Stone, J. M. Hamilton, H. Hassani, B. Mayer, J. Uhl, and J. Jenkins
Burden of illness of chronic, adult idiopathic thrombocytopenic purpura (ITP): A retrospective, longitudinal, cohort study, Mansoor Saleh and Kelly Grotzinger
Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes, James Slack, John D. Hainsworth, James Mason, Mansoor Saleh, David Rizzieri, Dan Douer, and Alan F. List
Submissions from 2005
Bexarotene improves TTP in untreated, advanced NSCLC, when given in combination with carboplatin/paclitaxel, R. Bordoni, Mansoor Saleh, M. Auerbach, F Steinbaum, J. D. Cuevas, S. Harris, and B. Howell
Bortezomib plus rituximab in patients with indolent non-hodgkin's lymphoma (NHL): A phase 2 study., Sven de Vos, Shaker Dakhil, Peter McLaughlin, Mansoor Saleh, Robert Belt, Christopher Flowers, Mark Knapp, Lowell Hart, Dipti Patel-Donnelly, and Martha Glenn
Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naïve advanced non–small-cell lung cancer, Francisco Robert, George Blumenschein, Roy S. Herbst, Frank Fossella, Jennifer Tseng, Mansoor Saleh, and Michael Needle
Effect of docetaxel chemotherapy on the activity of a gonadotropin releasing hormone vaccine in patients with advanced prostate cancer, Pierre L. Triozzi, Graeme B. Bolger, Jeffrey Neidhart Neidhart, John J. Rinehart, Mansoor Saleh, Karen O. Allen, Sandra Sellers, and Mary Waddell
Phase 2 results of ABT-751 in subjects with taxane-refractory breast cancer: Interim analysis, D. K. Washington, A. M. V. Storniolo, Mansoor Saleh, E. Tan-Chiu, A. Hagey, D. M. Medina, K. A. Meek, P. Cernohous, and G. B. Gordon Gordon
Submissions from 2004
Weekly oxaliplatin (OXA), 5-fluorouracil (FU) and leucovorin (LV) as first line treatment for advanced colorectal cancer (CRC) –A phase II study, A. Athanasiadis, N. Pissanidis, Mansoor Saleh, A. Moshidis, A. Chatzichristou, N. Makrantonakis, P. Kamentsidis, I. Natsiopoulos, and C. Christakis
cMulticenter, prospective, randomized, phase-II trial of sequential and concurrent oral bexarotene in combination with chemotherapy, in previously untreated patients with advanced NSCLC, R. Bordoni, L. Zemsky, Mansoor Saleh, C. Powell, and S. Harris
Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma, Mahmoud Hussein, James Mason, Mansoor Saleh, Richard Rifkin, and Farhad Ravandi
Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma, Mohamad Hussein, Mansoor Saleh, Farhad Ravandi, James Mason, Robert Rifkin, and Ralph Ellison
Tositumomab and Iodine I 131 Tositumomab (The BEXXAR® Therapeutic Regimen) produced ongoing, durable remissions of more than 5 years in 9 patients with Non-Hodgkin’s Lymphoma (NHL) in a pivotal study of patients refractory to their last chemotherapy., Mark Kaminski, Andrew Zelenetz, Oliver Press, Mansoor Saleh, John Leonard, Louis Fehrenbacher, Andrew Lister, Stewart Kroll, Richard Wahl, and Susan Knox
O1123 Posttraumatic deformity correction in the tibia using the Sheffield ring fixator., Amir Salama and Mansoor Saleh
Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression, Debu Tripathy, Mansoor Saleh, Dennis Slamon, Melody Cobleigh, Andrew Arnold, Joanne Mortimer, and George Sledge
Trastuzumab bei Patientinnen mit metastasiertem Mammakarzinom über die Erstlinientherapie hinaus, Debu Tripathy, Dennis Slamon, Michael Cobleigh, Arnold Arnold, Mansoor Saleh, Joyce Mortimer, Michael Murphy, and Sandra Steward
Submissions from 2003
Progressive deformity correction on the tibia using the Sheffield ring fixator (SRF)., Amir Salama and Mansoor Saleh
Submissions from 2002
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma, Leo Gordon, Thomas Witzig, Greg Wiseman, Ian Flinn, Stewart Spies, Daniel Silverman, Christos Emmanouilides, Mansoor Saleh, Larry Cripe, and Myron Czuczman
A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors, James Posey, Mohammad Khazaeli, Michael Bookman, Anahit Nowrouzi, William Grizzle, Jennifer Thornton, Delicia Carey, Jennifer Lorenz, Clay Siegall, and Mansoor Saleh
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial, Gregory Wiseman, Leo Gordon, Pratik Multani, Thomas Witzig, Stewart Spies, Nancy Bartlett, Russell Schilder Schilder, James Murray, Mansoor Saleh, and Roberta Allen